Trastuzumab (KANJINTI®)
- offers identical dosing schedules to trastuzumab RP for metastatic breast cancer, early breast cancer and metastatic gastric cancer1,2
- is the first and only trastuzumab biosimilar with single-switch data3
- has proven efficacy and safety similar to trastuzumab RP3
- NCCN guidelines for Breast Cancer recommend an FDA-approved biosimilar as an appropriate substitution for trastuzumab4
- #1 prescribed Trastuzumab Biosimilar in the US5
References:
1. Trastuzumab (KANJINTI) Philippines Prescribing Information. Nov 2019.
2. Herceptin (trastuzumab) Full Prescribing Info. Available at: https://www.mims.com/hongkong/drug/info/herceptin?type=full. Accessed May 5, 2021.
3. von Minckwitz G, Colleoni M, Kolberg HC, et al. Lancet Oncol. 2018;19(7):987-998.
4. National Comprehensive Cancer Network® (NCCN®) / NCCN Foundation®. NCCN Guidelines for Patients®: Metastatic Breast Cancer, 2020. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419. Accessed May 5, 2021.
5. Data on file, Amgen [#1 Trastuzumab Biosimilar]; Dec 2022. [https://www.kanjinti.com/]
PH-PM-AMGEN-Kanjinti-ONA-HCP-000001-01-2023
Zuellig Pharma Corporation
8th Flr The Curve Bldg, 32nd Cor 3rd Ave,
Bonifacio Global City,
Taguig City 1634
Tel: (+63-2) 8405 5121